Nocardiosis pulmonar tratada con tedizolid

Víctor Giménez-Arufe; José María Gutiérrez-Urbón; Marina Blanco-Aparicio; Enrique Míguez-Rey; María Isabel Martín-Herranz

doi:10.7399/fh.11256

Nocardiosis pulmonar tratada con tedizolid

Víctor Giménez-Arufe, José María Gutiérrez-Urbón, Marina Blanco-Aparicio, Enrique Míguez-Rey, María Isabel Martín-Herranz

Resumen

Palabras clave

Texto completo:

PDF (English) PDF

Referencias

Fatahi-Bafghi M. Nocardiosis from 1888 to 2017. Microb Pathog. 2018;114:369-84. DOI: 10.1016/j.micpath.2017.11.012

Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309:559-69. DOI: 10.1001/jama.2013.241

Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomized, double-blind, phase 3, noninferiority trial. Lancet Infect Dis. 2014;14(8):696-705. DOI: 10.1016/S1473-3099(14)70737-6

Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Tedizolid against Isolates of Nocardia. Antimicrob Agents Chemother. 2017;61(12):e01537-17. DOI: 10.1128/AAC.01537- 17

Moylett EH, Pacheco SE, Brown-Elliott BA, Perry TR, Buescher ES, Birmingham MC, et al. Clinical experience with linezolid for the treatment of Nocardia infection. Clin Infect Dis. 2003;36:313- 8. DOI: 10.1086/345907

Matin A, Sharma S, Mathur P, Apewokin SK. Myelosuppression- sparing treatment of central nervous system nocardiosis in a multiple myeloma patient utilizing a tedizolid-based regimen: a case report. Int J Antimicrob Agents. 2017;49(4):488-92. DOI: 10.1016/j.ijantimicag.2016.11.032

Shorr AF, Lodise TP, Corey GR, De Anda C, Fang E, Das AF, et al. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2015;59(2):864-71. DOI: 10.1128/AAC.03688-14

Lee EY, Caffrey AR. Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother. 2018;62:e01453-17. DOI: 10.1128/AAC.01453-17

Kim T, Wills A, Markus A, Prevots DR, Olivier KN. Safety and Tolerability of Long Term Use of Tedizolid for Treatment of Nontuberculous Mycobacterial Infections. Open Forum Infect Dis. 2016;3(Suppl 1):577. DOI: 10.1093/ofid/ofw172.440

Nigo M, Luce AM, Arias CA. Long-term Use of Tedizolid as Suppressive Therapy for Recurrent Methicillin-Resistant Staphylococcus aureus Graft Infection. Clin Infect Dis. 2018;66(12):1975-6. DOI: 10.1093/cid/ciy041

DOI: http://dx.doi.org/10.7399%2Ffh.11256